ARTICLE | Clinical News
EMA accepts MAA for Humira biosimilar from Fujifilm, Kyowa
June 9, 2017 7:51 PM UTC
Fujifilm Kyowa Kirin Biologics Co. Ltd., a JV between Fujifilm Holdings Corp. (Tokyo:4901) and Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), said EMA accepted an MAA for FKB327, a biosimilar of Humira adalimumab from AbbVie Inc. (NYSE:ABBV) (see BioCentury, April 2, 2012).
In Europe, Humira is approved for autoimmune indications including Crohn’s disease (CD), rheumatoid arthritis (RA), axial spondyloarthritis, psoriatic arthritis, plaque psoriasis, ulcerative colitis (UC) and juvenile idiopathic arthritis...
BCIQ Target Profiles